PDF factsheet
      Z

prevention in atrial fibrillation for patient with history of atrial fibrillation, clinical trials results

atorvastatin versus control
Ozaydin, 2006
atorvastatin 10 mg
versus
standard therapy
Persistent AF and scheduled ECopen
Follow-up duration: 3 months
atorvastatin versus placebo
Almroth, 2009
atorvastatin 80 mg daily
versus
placebo
patients with persistent atrial fibrillation undergoing electrical cardioversion double blind
Sweden
MIRACL (sub-group) (Schwartz), 2004
atorvastatin 80 mg
versus
placebo
Acute coronary syndromedouble blind
Follow-up duration: 16 weeks
Dernellis, 2006
atorvastatin 20–40 mg
versus
placebo
Paroxysmal AF with CRP between 0.8 and 13 mg/LNA
Follow-up duration: 4–6 months
candesartan versus placebo
CAPRAF (Tveit), 2007
NCT00130975
candesartan 8 mg once daily for 3-6 weeks before and candesartan 16 mg once daily for 6 months after electrical cardioversion
versus
placebo
patients undergoing electrical cardioversion for persistent AFdouble blind
Follow-up duration: 6 months
enalapril versus control
Ueng, 2003
enalapril
versus
control
atrial fibrillationopen
Follow-up duration: 270 days (range 61-575d)
irbesartan versus control
Madrid, 2002
irbesartan
versus
control
atrial fibrillationopen
Follow-up duration: 254 d (range 60-710)
irbesartan versus placebo
ACTIVE I, 2009
NCT00249795
irbesartan 300mg once daily
versus
placebo
patients with atrial fibrillation and with a systolic blood pressure of at least 110 mmHg associated with at least one major risk of vascular events double blind
Follow-up duration: 4.1 years
lisinopril versus placebo
Van den Burg, 1995
lisinopril
versus
placebo
atrial fibrillation, congestive heart failuredouble blind
Follow-up duration: 84 days
pravastatin versus control
Tveit, 2004
pravastatin 40 mg
versus
standard therapy
AF >48 h and scheduled EC
Follow-up duration: 6 weeks
valsartan versus placebo
GISSI-AF (Disertori), 2009
NCT00376272
valsartan
versus
placebo
patients in sinus rhythm but with either two or more documented episodes of atrial fibrillation in the previous 6 months or successful cardioversion for atrial fibrillation in the previous 2 weeks and with underlying cardiovascular disease, diabetes, or left atrial enlargementdouble blind
Follow-up duration: 1 year

  Options


in first

in second

  Filter